Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aneurotech BV is currently prosecuting patents in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is being handled by 1 distinct examiner. This singular focus shows that the company's current efforts are dedicated to a specific advancement in the biotech field. The involvement of 1 distinct art unit further confirms the specialized nature of the pending application. This lack of complexity in the prosecution structure may allow for a more focused dialogue between the company and the USPTO.
The busiest examiner for the portfolio is CHONG, YONG SOO, who is managing 1 pending office action. Since there is only 1 pending action for the entire company, this examiner holds the key to the company's current patent objectives. The data reveals a very direct prosecution environment with 1 distinct examiner and 1 distinct art unit. This concentration means that the company's immediate patent prospects are entirely dependent on the results of this single matter. Practitioners can focus their strategy on the specific requirements and feedback provided by this single examiner within their specialized art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18328682 | ADJUNCTIVE THERAPY FOR DEPRESSION | CHONG, YONG SOO | 121d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18328682 | ADJUNCTIVE THERAPY FOR DEPRESSION | CHONG, YONG SOO | 121d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18328682 | ADJUNCTIVE THERAPY FOR DEPRESSION | CHONG, YONG SOO | 1623 | §102§103 | Final Rejection | 121d overdue | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial